If recapitulatedin humans, such a minimal dosing regimen would revolutionize ERα+breast cancer therapeutic management through improved treatment compliance,quality-of-life, and long-term outcomes for breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.